Rokote Laboratories

Executive Summary

Rokote Laboratories Finland Oy is a preclinical-stage biotechnology company spun out from the University of Helsinki and the University of Eastern Finland in 2020. The company is developing a proprietary universal intranasal vaccine platform (FINVAC) designed to induce robust mucosal immunity against respiratory pathogens. Its lead candidate is a nasal COVID-19 vaccine that has completed a first Phase I trial and is now preparing for a second Phase I study. The platform's ability to target multiple respiratory viruses positions it as a potential game-changer in pandemic preparedness and routine vaccination. Despite being early-stage, Rokote's innovative approach and strong academic roots give it a unique niche in the competitive vaccine landscape. The company is privately held and has not disclosed total funding or valuation, but its focus on needle-free, mucosal vaccines aligns with global trends toward improved vaccine delivery and broader immune protection. Key risks include the technical challenges of demonstrating intranasal vaccine efficacy and the need for substantial capital to advance through clinical trials.

Upcoming Catalysts (preview)

• H2 2026Initiation of second Phase I trial for nasal COVID-19 vaccine70% success
• H1 2027Interim safety and immunogenicity data from the second Phase I trial60% success
• Q4 2026Potential partnership or licensing deal for FINVAC platform30% success